BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐... von Borthakur, Gautam, Ofran, Yishai, Tallman, Martin S., Foran, James, Uy, Geoffrey L., DiPersio, John F., Showel, Margaret M., Shimoni, Avichai, Nagler, Arnon, Rowe, Jacob M., Altman, Jessica K., Abraham, Michal, Peled, Amnon, Shaw, Stephen, Bohana‐Kashtan, Osnat, Sorani, Ella, Pereg, Yaron, Foley‐Comer, Adam, Oberkovitz, Galia, Lustig, Tzipi M., Glicko‐Kabir, Irit, Aharon, Arnon, Vainstein‐Haras, Abi, Kadosh, Shaul E., Samara, Emil, Al‐Rawi, Ahmed N., Pemmaraju, Naveen, Bueso‐Ramos, Carlos, Cortes, Jorge E., Andreeff, Michael

Volltext

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial von Bockorny, Bruno, Semenisty, Valerya, Macarulla, Teresa, Borazanci, Erkut, Wolpin, Brian M., Stemmer, Salomon M., Golan, Talia, Geva, Ravit, Borad, Mitesh J., Pedersen, Katrina S., Park, Joon Oh, Ramirez, Robert A., Abad, David G., Feliu, Jaime, Muñoz, Andres, Ponz-Sarvise, Mariano, Peled, Amnon, Lustig, Tzipora M., Bohana-Kashtan, Osnat, Shaw, Stephen M., Sorani, Ella, Chaney, Marya, Kadosh, Shaul, Vainstein Haras, Abi, Von Hoff, Daniel D., Hidalgo, Manuel

Volltext

Fas Ligand as a Tool for Immunosuppression and Generation of Immune Tolerance von Bohana‐Kashtan, Osnat, Civin, Curt I.

Volltext

Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement‐mediated lysis von Bohana‐Kashtan, Osnat, Pinna, Lorenzo A., Fishelson, Zvi

Volltext

Abstract 1320: NanoGhost: Harnessing the power of stem cell in an off-the-shelf novel targeted nano-delivery platform von Machluf, Marcelle, Hamias, Shani, Levii, Lior, Kashtan, Osnat Bohana

Volltext

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death von Xia, Jun, Sun, Stephanie, Jotte, Matthew RM, Uy, Geoffrey L., Bohana-Kashtan, Osnat, Sorani, Ella, Vainstein, Abi, Peled, Amnon, Link, Daniel C.

Volltext

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma von Uy, Geoffrey L., Kadia, Tapan M., Stock, Wendy, Brammer, Jonathan E, Bohana-Kashtan, Osnat, Vainstein, Abi, Sorani, Ella, Chen, Hemda, DiPersio, John F., Link, Daniel C.

Volltext

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation... von Rettig, Michael P., Uy, Geoffrey L., Bashey, Asad, Devine, Steven, Jaglowski, Samantha, Vainstein, Abi, Sorani, Ella, Chen, Hemda, Bohana-Kashtan, Osnat, Shaw, Stephen, Westervelt, Peter, DiPersio, John F.

Volltext

The CXCR4 Antagonist, BL8040, Is Highly Active Against Human T-ALL in Preclinical Models von Xia, Jun, Jotte, Matthew RM, Sun, Stephanie, Uy, Geoffrey L., Vainstein, Abi, Sorani, Ella, Bohana-Kashtan, Osnat, Shaw, Stephen, Link, Daniel C.

Volltext

Cell signals transduced by complement von Bohana-Kashtan, Osnat, Ziporen, Lea, Donin, Natalie, Kraus, Sarah, Fishelson, Zvi

Volltext

1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase von Yacovan, Avihai, Ozeri, Rachel, Kehat, Tzofit, Mirilashvili, Sima, Sherman, Daniel, Aizikovich, Alex, Shitrit, Alina, Ben-Zeev, Efrat, Schutz, Nili, Bohana-Kashtan, Osnat, Konson, Alexander, Behar, Vered, Becker, Oren M.

Volltext

Long-Term Efficacy of GMP Grade Xeno-Free hESC-Derived RPE Cells Following Transplantation von McGill, Trevor J, Bohana-Kashtan, Osnat, Stoddard, Jonathan W, Andrews, Michael D, Pandit, Neelay, Rosenberg-Belmaker, Lior R, Wiser, Ofer, Matzrafi, Limor, Banin, Eyal, Reubinoff, Benjamin, Netzer, Nir, Irving, Charles

Volltext

Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand von Bohana-Kashtan, Osnat, Morisot, Sebastien, Hildreth, Richard, Brayton, Cory, Levitsky, Hyam I, Civin, Curt I

Volltext

Preparation of photoreceptors for the treatment of retinal diseases von Bohana-Kashtan, Osnat

Volltext bestellen

Abstract 3219: Changing the metabolism of cancer cells with PKM2 activators - a path to a cancer metabolism drug von Behar, Vered, Bohana-Kashtan, Osnat, Shitrit, Alina, Ben-Zeev, Efrat, Konson, Alexander, Ozeri, Rachel, Kehat, Tzofit, Mirilashvili, Sima, Schutz, Nili C., Yacovan, Avihai, Becker, Oren M.

Volltext

Abstract 4065: Modulation of cancer metabolism with novel PKM2 activators exerts anti-tumor activity von Behar, Vered, Bohana-Kashtan, Osnat, Shitrit, Alina, Sherman, Daniel, Schutz, Nili C., Yakovan, Avihai, Becker, Oren M.

Volltext

The YAP Transcriptional Co-Activator Is Not Required for Mouse Hematopoiesis, at Steady State or After 5FU Treatment von Cheng, Wen-Chih, Bohana-Kashtan, Osnat, Morisot, Sebastien, Zhang, Nailing, Chen, Qian, Pan, Duojia, Civin, Curt I.

Volltext

Identification of New Alloantigen-Reactive CD8+ Cytotoxic and Suppressor T Cell Subpopulations von Bohana-Kashtan, Osnat, Levitsky, Hyam, Civin, Curt I.

Volltext

Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand1 von Bohana-Kashtan, Osnat, Morisot, Sebastien, Hildreth, Richard, Brayton, Cory, Levitsky, Hyam I., Civin, Curt I.

Volltext

Preparation of photoreceptors for the treatment of retinal diseases von Bohana-Kashtan, Osnat

Volltext bestellen